


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound of formula I



in which

R is -OH, -OA, phenoxy, Ar, -O-CO-A,  $SO_3H$ ,  $SO_3A$ , -OSO<sub>3</sub>H, -OSO<sub>3</sub>A, -OSO<sub>2</sub>A,  $SO_2A$ , Hal, COOH, COOA, CONH<sub>2</sub>, NHSO<sub>2</sub>A, COA, CHO or  $SO_2NH_2$ , or  
two radicals R together are methylenedioxy or ethylenedioxy,

X is OH, or  
two radicals X together are methylenedioxy or ethylenedioxy,

Ar is phenyl which is unsubstituted or monosubstituted, disubstituted or trisubstituted by A,

A is an unbranched or branched alkyl having 1-10 carbon atoms, in which 1-7 H atoms are optionally replaced by F,

Hal is F, Cl, Br or I,

n is 1, 2, 3 or 4, and

m is 1, 2, 3, 4 or 5, or

a salt thereof, or a solvate

or a mixture of stereoisomers or an isolated stereoisomer thereof.

2. (Currently Amended) A compound according to Claim 1,

in which

R is -OH or -OA, and

X is OH, or

a salt thereof, or a solvate

or a mixture of stereoisomers or an isolated stereoisomer thereof.

3. (Currently Amended) A compound according to Claim 1,  
in which

R is -OH or -OA,

X is OH,

A is an unbranched or branched alkyl having 1-6 carbon atoms,

n is 1 or 2, and

m is 1, 2 or 3, or

a salt thereof, ~~or a solvate~~

or a mixture of stereoisomers or an isolated stereoisomer thereof.

4. (Currently Amended) A compound according to Claim 1,  
in which

R is -OH or -OA, or

two radicals R together are methylenedioxy or ethylenedioxy,

X is OH,

A is an unbranched or branched alkyl having 1-6 carbon atoms,

n is 1 or 2, and

m is 1, 2 or 3, or


a salt thereof, ~~or a solvate~~

or a mixture of stereoisomers or an isolated stereoisomer thereof.

5. (Currently Amended) A compound according to Claim 1 selected from  
5-hydroxy-2-(2',4'-dihydroxybenzoyl)chromone,  
5-hydroxy-2-(2'-hydroxy-4',5'-methylenedioxybenzoyl)chromone,  
6-hydroxy-2-(2'-hydroxy-4',5'-methylenedioxybenzoyl)chromone, or  
6,7-methylenedioxy-2-(2'-hydroxy-4',5'-methylenedioxybenzoyl)chromone, or  
a salt thereof, ~~or a solvate~~  
or a mixture of stereoisomers or an isolated stereoisomer thereof.


7 ~~g.~~ (Currently Amended) A process for preparing a compound according to Claim 1 or a salt thereof, ~~or a solvate~~ or a mixture of stereoisomers or an isolated stereoisomer thereof comprising

a) reacting a compound of formula II




in which

X and n are as defined in Claim 1,  
with a compound of formula III




in which A is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,  
to give a compound of formula IV




in which X and n are as defined in Claim 1, and A is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

- b) then hydrolysing the compound of formula IV to a compound of formula V




in which X and n are as defined in Claim 1,

- c) then converting the compound of formula V to a compound of formula VI



in which X and n are as defined in Claim 1,

and then reacting the compound of formula VI with a compound of formula VII



in which R and m are as defined in Claim 1,

in a Friedel-Crafts acylation to give a compound of the formula I,

and/or

- d) converting a compound of formula I ~~is converted~~ into a salt ~~or into a solvate~~ and/or isolating a stereoisomer of a compound of formula I ~~is isolated~~.

8 A. (Currently Amended) A pharmaceutical composition comprising <sup>an effective amount of</sup> a compound according to Claim 1 or a salt thereof, ~~or a solvate~~ or a mixture of stereoisomers or an isolated stereoisomer thereof and one or more pharmaceutically acceptable excipients and/or

adjuvants.

8-10. (Cancelled)

11. (Currently Amended) A method of treating a pre-existing condition, which is monocytic leukaemia, lung adenocarcinoma, small cell lung carcinoma, pancreatic cancer, glioblastoma or breast carcinoma in a mammal comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.

12-13. (Cancelled)

14. (Currently Amended) A method of treating a pre-existing condition, which is retinal vascularisation in a mammal comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.

15. (Currently Amended) A method of treating a pre-existing condition, which is diabetic retinopathy in a mammal comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.

16. (Currently Amended) A method of treating a pre-existing condition, which is an age-related macular degeneration in a mammal comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.

17. (Cancelled)

18. (Currently Amended) A method of treating a pre-existing condition, which is rheumatoid arthritis, psoriasis, contact dermatitis or a delayed hypersensitivity reaction in a mammal comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.

19-20. (Cancelled)

21. (Currently Amended) A method of treating a pre-existing condition, which is osteosarcoma, osteoarthritis or rickets comprising administering to a patient in need thereof a pharmaceutical composition according to claim 7.

22. (Original) A pharmaceutical composition according to claim 7, further comprising an additional pharmaceutically active compound.

23. (Currently Amended) A kit comprising separate packs of

- (a) a pharmaceutical composition according to Claim 7 or a compound of formula I or a salt thereof, ~~or a solvate~~ or a mixture of stereoisomers or an isolated stereoisomer thereof,
- and

- (b) an additional pharmaceutically active compound or composition.

24. (Withdrawn) A method according to claim 11, further comprising administering an oestrogen receptor modulator, an androgen receptor modulator, a retinoid receptor modulator, a cytotoxic agent, an antiproliferative agent, a prenyl-protein transferase inhibitor, an HMG-CoA reductase inhibitor, an HIV protease inhibitor, a reverse transcriptase inhibitor or an angiogenesis inhibitor.

25. (Withdrawn) A method according to claim 11, further comprising performing radiotherapy on said mammal.

26-27. (Cancelled)

28. (Original) A food supplement comprising a compound of claim 1.

9 29. (Original) A cosmetic composition comprising a compound of claim 1, an effective amount of  
and a cosmetically acceptable excipient


10  
 30. (Currently Amended) A method of protecting the skin of a patient and  
 from oxidative stress or damage of the sun,  
 therein the proteins of the skin from stress, comprising applying a cosmetic composition of claim  
 9 29 to the skin.

11  
 31. (Original) A topically applicable cosmetic composition comprising a  
 compound of claim 1. 29 9

12 32. (Previously Presented) A cosmetic composition containing 0.0001 to 50%  
 by weight of a compound of claim 1. 29 9

33. (Cancelled)

6 34. (Previously Presented) A compound of formula I according to Claim 1,



in which

R is -OH, -OA, phenoxy, Ar, -O-CO-A, SO<sub>3</sub>H, SO<sub>3</sub>A, -OSO<sub>3</sub>H, -OSO<sub>3</sub>A, -OSO<sub>2</sub>A, SO<sub>2</sub>A, Hal, COOH, COOA, CONH<sub>2</sub>, NHSO<sub>2</sub>A, COA, CHO or SO<sub>2</sub>NH<sub>2</sub>, or two radicals R together are methylenedioxy or ethylenedioxy,

X is OH, or two radicals X together are methylenedioxy or ethylenedioxy,

Ar is phenyl which is unsubstituted or monosubstituted, disubstituted or trisubstituted by A,

A is an unbranched or branched alkyl having 1-10 carbon atoms, in which 1-7 H atoms are optionally replaced by F,

Hal is F, Cl, Br or I,

n is 1, 2, 3 or 4, and

m is 1, 2, 3, 4 or 5, or  
a salt thereof.